 Omalizumab
"Omalizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA.
| Descriptor ID |
D000069444
|
| MeSH Number(s) |
D12.776.124.486.485.114.071.500 D12.776.124.486.485.114.224.060.844 D12.776.124.790.651.114.071.500 D12.776.124.790.651.114.224.060.844 D12.776.377.715.548.114.071.500 D12.776.377.715.548.114.224.200.844
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Omalizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Anti-Idiotypic [D12.776.124.486.485.114.071]
- Omalizumab [D12.776.124.486.485.114.071.500]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Omalizumab [D12.776.124.486.485.114.224.060.844]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Anti-Idiotypic [D12.776.124.790.651.114.071]
- Omalizumab [D12.776.124.790.651.114.071.500]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Omalizumab [D12.776.124.790.651.114.224.060.844]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Anti-Idiotypic [D12.776.377.715.548.114.071]
- Omalizumab [D12.776.377.715.548.114.071.500]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Omalizumab [D12.776.377.715.548.114.224.200.844]
Below are MeSH descriptors whose meaning is more specific than "Omalizumab".
This graph shows the total number of publications written about "Omalizumab" by people in this website by year, and whether "Omalizumab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 2 | 2 | | 2007 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2015 | 1 | 1 | 2 | | 2016 | 1 | 2 | 3 | | 2017 | 3 | 0 | 3 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 3 | 4 | | 2021 | 0 | 1 | 1 | | 2022 | 1 | 0 | 1 | | 2023 | 0 | 2 | 2 | | 2024 | 5 | 2 | 7 | | 2025 | 2 | 0 | 2 | | 2026 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Omalizumab" by people in Profiles.
-
Anderson B, Pascal C, Butler MGK, Chin AR, Long AJ, Sindher SB, Anagnostou A, Arasi S, Bégin P, Ciaccio CE, Eiwegger T, Fiocchi A, Fleischer DM, Garcia-Llorett M, Kim EH, Leonard S, Maskatia ZR, Perrett KP, Shreffler W, Upton J, Chinthrajah RS. Biologics and Novel Therapeutics in Food Allergy. J Allergy Clin Immunol Pract. 2026 Apr; 14(4):762-770.
-
Sindher SB, Chehade M, Dellon ES, Jones SM, Spergel JM, Lin A, Rogers NH, Wood RA, Shreffler WG, Burk CM, Kim EH, Virkud YV, Scurlock AM, Lanser BJ, Hui-Beckman JW, Vickery BP, Bird JA, Parrish C, Wang J, Sicherer SH, Brown-Whitehorn T, Dantzer J, Ruiz J, Wheatley LM, Chinthrajah RS. Management of Gastrointestinal Symptoms During Oral Immunotherapy: Guidance from OUtMATCH Investigators. J Allergy Clin Immunol Pract. 2026 Apr; 14(4):772-779.
-
Chinthrajah RS, Kulis M, Jones SM, Sicherer S, Wang J, Shreffler W, Burk CM, Kim E, Keet C, Sindher S, Long AJ, Scurlock AM, Lanser BJ, Hui-Beckman JW, Vickery B, Ezhuthachan ID, Bird JA, Parrish C, Spergel JM, Brown-Whitehorn T, Dantzer J, Ligueros-Saylan M, Tassinari P, Olsson J, Iqbal A, Ozanne M, Huckabee C, Rogers N, Yovetich N, Lin A, Brittain E, Wheatley LM, Togias A, Wood RA. Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies. J Allergy Clin Immunol. 2026 Feb; 157(2):442-453.
-
Dantzer J, Virkud Y, Wang J, Sicherer S, Groetch M, Shreffler W, Pyle D, Kim E, Keet C, Kulis M, Mudd K, Sindher S, Long A, Scurlock AM, Jones SM, Leung D, Lanser B, Vickery B, Ezhuthachan ID, Bird JA, Parrish C, Spergel JM, Brown-Whitehorn T, Ligueros-Saylan M, Tassinari P, Iqbal A, Sibanda D, Huckabee C, Yovetich N, Rogers N, Lin A, Wheatley LM, Togias A, Chinthrajah RS, Wood RA. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025 Aug; 156(2):394-405.
-
Brough HA, Kim EH, Anagnostou A, Lanser BJ, Chinthrajah RS, Sindher SB. Treatment of Food Allergy: Immunotherapy, Omalizumab, or Both. J Allergy Clin Immunol Pract. 2025 Apr; 13(4):731-739.
-
Anagnostou A, Bird JA, Chinthrajah S, Dribin TE, Fleischer DM, Kim E, Nowak-Wegrzyn A, Rachid R, Shaker MS, Shreffler W, Sicherer S, Tam J, Vickery BP, Virkud YV, Wang J, Young M, Greenhawt M. The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2025 Jan; 155(1):62-69.e1.
-
Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit? Ann Allergy Asthma Immunol. 2025 Jan; 134(1):110-121.
-
Boyd JT, Khanwalkar AR. Biologics in Chronic Rhinosinusitis: Current and Emerging. Immunol Allergy Clin North Am. 2024 11; 44(4):657-671.
-
Shaker M, Anagnostou A, Abrams EM, Lee M, Conway AE, Hsu Blatman KS, Oppenheimer J, Greenhawt M. The Cost-Effectiveness of Omalizumab for Treatment of Food Allergy. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2481-2489.e1.
-
Keller L, Stitt J. Chronic Spontaneous Urticaria: Quality of Life and Economic Impacts. Immunol Allergy Clin North Am. 2024 08; 44(3):453-467.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|